Tapentadol IR (CG5503) + Placebo + Oxycodone HCL IR + Tapentadol IR (CG5503)
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Arthroplasty
Conditions
Arthroplasty
Trial Timeline
Oct 1, 2006 → Dec 1, 2007
NCT ID
NCT00364533About Tapentadol IR (CG5503) + Placebo + Oxycodone HCL IR + Tapentadol IR (CG5503)
Tapentadol IR (CG5503) + Placebo + Oxycodone HCL IR + Tapentadol IR (CG5503) is a phase 3 stage product being developed by Johnson & Johnson for Arthroplasty. The current trial status is terminated. This product is registered under clinical trial identifier NCT00364533. Target conditions include Arthroplasty.
What happened to similar drugs?
1 of 2 similar drugs in Arthroplasty were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00364533 | Phase 3 | Terminated |
Competing Products
9 competing products in Arthroplasty
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DU-176b | Daiichi Sankyo | Phase 2 | 35 |
| YM150 + Warfarin | Astellas Pharma | Phase 2 | 35 |
| Zoledronic acid 5mg | Novartis | Approved | 35 |
| Denosumab | Amgen | Phase 2 | 35 |
| JNJ-70033093 25 mg + JNJ-70033093 50 mg + JNJ-70033093 100 mg + JNJ-70033093 200 mg + Placebo + Enoxaparin 40 mg | Bristol Myers Squibb | Phase 2 | 35 |
| Enoxaparin sodium | Sanofi | Phase 3 | 40 |
| 48-hour ropivacaine infusions + Single dose ropivacaine + Patient controlled analgesics | Sanofi | Pre-clinical | 26 |
| Enoxaparin + Apixaban + BAY1213790 | Bayer | Phase 2 | 32 |
| Rivaroxaban (Xarelto, BAY59-7939) | Bayer | Pre-clinical | 23 |